Cost-effectiveness analysis: controlled-release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-Combi) study
Saito I, Fujikawa K, Saruta T, Tomita F, Kimura H, Nagakura T, Hiraoka T

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
18957811

DOI
10.1291/hypres.31.1399

Indexing Status
Subject indexing assigned by NLM

MeSH
Amlodipine /administration & dosage /economics; Cost-Benefit Analysis; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Humans; Hypertension /drug therapy /economics; Japan; Nifedipine /administration & dosage /economics; Randomized Controlled Trials as Topic; Tetrazoles /administration & dosage /economics; Valine /administration & dosage /analogs & derivatives; Valsartan

AccessionNumber
22009100015

Date bibliographic record published
31/03/2009